Flamel Technologies SA (FLML)

10.27
0.49 4.55
NASDAQ : Health Care
Prev Close 10.76
Open 10.50
Day Low/High 10.13 / 10.81
52 Wk Low/High 7.56 / 15.45
Volume 166.13K
Avg Volume 105.70K
Exchange NASDAQ
Shares Outstanding 41.24M
Market Cap 428.50M
EPS 1.00
P/E Ratio 16.76
Div & Yield N.A. (N.A)
Flamel Technologies' CEO Discusses Q4 2011 Results - Earnings Call Transcript

Flamel Technologies' CEO Discusses Q4 2011 Results - Earnings Call Transcript

Flamel Technologies' CEO Discusses Q4 2011 Results - Earnings Call Transcript

Flamel Technologies Announces Acquisition Of Éclat Pharmaceuticals

Flamel Technologies Announces Acquisition Of Éclat Pharmaceuticals

Flamel Technologies (NASDAQ: FLML) today announced the acquisition of Éclat Pharmaceuticals, a specialty pharmaceutical company that is focused on the development, approval, and commercialization of niche brands...

Flamel Technologies Announces Fourth Quarter And Year-End 2011 Results

Flamel Technologies Announces Fourth Quarter And Year-End 2011 Results

Flamel Technologies (NASDAQ: FLML) today announced its financial results for the fourth quarter and year ended December 31, 2011.

Flamel Technologies's CEO Discusses Q3 2011 Results - Earnings Call Transcript

Flamel Technologies's CEO Discusses Q3 2011 Results - Earnings Call Transcript

Flamel Technologies's CEO Discusses Q3 2011 Results - Earnings Call Transcript

Flamel Technologies Announces Profitable Third Quarter Results

Flamel Technologies Announces Profitable Third Quarter Results

Flamel Technologies (Nasdaq:FLML) today announced its financial results for the third quarter of 2011.

Flamel Technologies Announces Multi-Year Supply Agreement With GlaxoSmithKline For Coreg CR™ Microparticles

Flamel Technologies Announces Multi-Year Supply Agreement With GlaxoSmithKline For Coreg CR™ Microparticles

Flamel Technologies (Nasdaq: FLML) announced today that it has entered into a multi-year supply agreement with GlaxoSmithKline (NYSE: GSK) for the production of Coreg CR microparticles.

Eagle Pharmaceuticals And Flamel Technologies Announce Eagle To License Medusa Technology For Extended-Release Of Tigecycline

Eagle Pharmaceuticals And Flamel Technologies Announce Eagle To License Medusa Technology For Extended-Release Of Tigecycline

Eagle Pharmaceuticals, Inc. and Flamel Technologies SA (NASDAQ: FLML) today announced that the two companies have entered into a license and development agreement for the development of a Medusa-based hydrogel depot...

Flamel Technologies CEO Discusses Q2 2011 Results - Earnings Call Transcript

Flamel Technologies CEO Discusses Q2 2011 Results - Earnings Call Transcript

Flamel Technologies CEO Discusses Q2 2011 Results - Earnings Call Transcript

Flamel Technologies And Digna Biotech Announce Multiple Product Development Agreement

Flamel Technologies And Digna Biotech Announce Multiple Product Development Agreement

Flamel Technologies SA (NASDAQ: FLML) and Digna Biotech SL today announced that the two companies have entered into a joint development agreement for the pre-clinical and clinical development of multiple products.

Flamel Technologies Announces Results Of Annual Meeting

Flamel Technologies Announces Results Of Annual Meeting

Flamel Technologies S.A.

Flamel Technologies Announces Nomination Of Ambassador Craig Stapleton, Dr. Catherine Bréchignac And Mr. Guillaume Cerutti For Election To The Board Of Directors

Flamel Technologies Announces Nomination Of Ambassador Craig Stapleton, Dr. Catherine Bréchignac And Mr. Guillaume Cerutti For Election To The Board Of Directors

Flamel Technologies (Nasdaq: FLML) announced today that the Board of Directors has nominated Dr.

Flamel Technologies CEO Discusses Q1 2011 Results - Earnings Call Transcript

Flamel Technologies CEO Discusses Q1 2011 Results - Earnings Call Transcript

Flamel Technologies CEO Discusses Q1 2011 Results - Earnings Call Transcript

Flamel Technologies Announces Expanded Partnership Relations; First Quarter Results

Flamel Technologies Announces Expanded Partnership Relations; First Quarter Results

Flamel Technologies (Nasdaq: FLML) today announced its financial results for the first quarter of 2011.

Flamel Technologies Announces Filing Of Lawsuit

Flamel Technologies Announces Filing Of Lawsuit

Flamel Technologies (NASDAQ:FLML) announced today that the Company has filed a lawsuit in the U.

Flamel Technologies Announces Micropump® License Agreement; $3 Million Upfront Payment

Flamel Technologies Announces Micropump® License Agreement; $3 Million Upfront Payment

Flamel Technologies (NASDAQ: FLML) announced today that it has entered into a license agreement with a leading specialty pharmaceutical company for development and commercialization of two molecules for pain ...

Flamel Technologies CEO Discusses Q4 2010 Results - Earnings Call Transcript

Flamel Technologies CEO Discusses Q4 2010 Results - Earnings Call Transcript

Flamel Technologies CEO Discusses Q4 2010 Results - Earnings Call Transcript

Flamel Technologies Announces Fourth Quarter And Year-End 2010 Results

Flamel Technologies Announces Fourth Quarter And Year-End 2010 Results

Flamel Technologies (NASDAQ: FLML) today announced its financial results for the fourth quarter and year ended December 31, 2010.

Flamel Technologies CEO Discusses Q3 2010 Results - Earnings Call Transcript

Flamel Technologies CEO Discusses Q3 2010 Results - Earnings Call Transcript

Flamel Technologies CEO Discusses Q3 2010 Results - Earnings Call Transcript

Flamel Technologies Announces Third Quarter Results; Achievement Of Second Milestone In Fourth Quarter With Merck Serono

Flamel Technologies (Nasdaq:FLML) today announced its financial results for the third quarter of 2010.

Flamel Technologies Achieves Clinical Milestone With Merck Serono On An Extended Release Formulation Of Interferon Beta-1a

Flamel Technologies (Nasdaq: FLML) announced today that it has achieved a clinical development milestone under the terms of its license agreement with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, to...

Flamel Technologies To Present At The UBS Global Life Sciences Conference In New York

Flamel Technologies (NASD: FLML) announced today that its chief executive officer, Stephen H.

Flamel Technologies SA Q2 2010 Earnings Call Transcript

Flamel Technologies SA Q2 2010 Earnings Call Transcript

Flamel Technologies SA Q2 2010 Earnings Call Transcript

Flamel Technologies Announces Three New Partnership Agreements; Second Quarter 2010 Results

Flamel Technologies (Nasdaq:FLML) today announced three new partnership agreements and its financial results for the second quarter of 2010.

Flamel Technologies Announces Results Of Annual Meeting

Flamel Technologies S.A.

Flamel Technologies Announces Expanded Partnership Relations; First Quarter Results

Flamel Technologies (Nasdaq: FLML) today announced its financial results for the first quarter of 2010.

Thursday's Health Winners & Losers

Thursday's Health Winners & Losers

Altus got its hormone drug, but gave up 40% in the market.

Wednesday's Health Winners & Losers

Wednesday's Health Winners & Losers

GPC Biotech and Spectrum Pharmaceuticals rose on a new drug application.

Wednesday's Small-Cap Winners & Losers

Wednesday's Small-Cap Winners & Losers

Beacon Power climbs on production news.

Takeover Rumors Boost Rio Tinto

Takeover Rumors Boost Rio Tinto

The mining giant could be a target of a joint bid by BHP Billiton and Companhia Vale do Rio Doce.

Challenges Persist for Glaxo

Challenges Persist for Glaxo

Fans say the company is too big to fail, but it's also too big to grow much without developing more hits.